



October 13, 2009

Cynthia Tudor, Ph.D.
Director, Medicare Drug Benefit and C&D Data Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244-1850

Dear Dr. Tudor:

This is a response to your letter requesting that the FDA provide an updated version of the May 2009 “Non-Matched NDC List.” More specifically, you requested that staff in the Center for Drug Evaluation and Research/Office of Compliance (CDER/OC) develop and provide an updated version of a “Non-Matched NDC List” that resulted from CDER/OC staff’s comparison of NDCs in the FDA’s NDC Directory with NDCs included in a National Library of Medicine database. We understand that CMS intends to compare the updated data that FDA has provided to the database that CMS uses to evaluate reimbursement claims before CMS posts a final Non-Matched NDC List on CMS’s website. CMS intends to use the resulting updated list to enable CMS’s processing systems beginning on or around January 1, 2010, to reject prescription drug event (PDE) submissions from Part D sponsors for NDCs identified on the final Non-Matched NDC list once CMS posts it, so that those PDEs are not processed or paid automatically.

Basic FDA Drug Listing Requirements

Under section 510 of the Federal Food, Drug and Cosmetic Act, as amended (“the Act”), and Part 207 of FDA’s regulations, with some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States or that are offered for import into the United States must be registered with the FDA. *See* 21 U.S.C. §§ 360(b), (c), (d), and (i). Every person who registers must, at the time of initial registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution. 21 U.S.C. § 360(j)(1). *See also* 21 C.F.R. 207.20. Drug listing information must be updated in June and December each year. These updates must include drugs not previously listed (if any), and certain changes to information for previously listed drugs. 21 U.S.C. § 360(j)(2); 21 CFR 207.21(b), 207.30.

Prescription drug products that are properly listed appear in the FDA’s NDC Directory. FDA does not consider a drug properly listed unless all data provided to the FDA for the product is correct and complete. However, neither the assignment of an NDC number nor inclusion in the NDC Directory denotes FDA approval of the product.

We understand that CMS is considering a drug product’s inclusion in the NDC Directory in reviewing whether such drug products may be eligible or covered under one or more programs administered by CMS. Our staff relies on drug listing data in responding to CMS inquiries about

whether particular drugs have, for example, been approved by FDA for safety and effectiveness; commercially used or sold in the U.S. prior to 1962, or are identical, related or similar, as defined by 21 CFR 310.6, to such a drug; or have been subject to a final “new drug” determination under the Act. Therefore, FDA can only provide CMS with regulatory status determinations through our regular processes if a drug product is properly listed.

FDA Development of the Updated Non-Matched NDC List (CY 2010)

CDER/OC staff compared NDCs in the FDA’s NDC Directory as of September 30, 2009 with NDC data from a National Library of Medicine database as of August 3, 2009. CDER/OC staff reviewed the resulting non-matching NDC data, which contained a list of NDCs, trade names, ingredients, and other general product parameters.

As with the Initial Non-Matched NDC List, CDER/OC staff identified certain types of products that would not ordinarily appear on the FDA NDC Directory so they could be excluded from the Updated Non-Matched NDC List. For example, the current edition of the NDC Directory is limited to prescription drugs and insulin products that have been manufactured, prepared, propagated, compounded, or processed by registered establishments for commercial distribution. We excluded from the updated Non-Matched NDC List products that we identified as not insulin products or prescription drug products in final dosage form. We also excluded products that were clearly identifiable as bulk chemicals, devices, or device kits. Products that could not be clearly identified as belonging to one of the above categories may remain on the list.

For the updated version, FDA/CDER/OC staff also removed from the resulting, updated Non-Matched NDC data the following products: NDCs associated with products identified by FDA and establishments as discontinued; NDCs with inactive Labeler Codes; and NDCs identified by industry as incorrectly excluded from the NDC Directory (and thus identified on the Initial Non-Matched NDC List), that FDA has verified the registrant properly listed by submitting accurate and complete listing information for that product.

Based on our staff’s review of the updated Non-Matched NDC data and FDA NDC Directory data, as well as our experience with FDA’s drug registration and listing system, subject to the qualifications and limitations described below, CDER/OC affirms that NDCs appearing on the updated Non-Matched NDC data FDA has provided could not be matched with NDCs in FDA’s NDC Directory as of September 30, 2009. This includes NDCs not submitted to FDA and NDCs included in listing submissions that were not properly completed. Again, we understand CMS may further revise or refine that data before posting a final updated Non-Matched NDC List.

Limitations of the NDC Directory and the Non-Matched NDC List

There are differences and limitations in the data maintained by the data sets used to create the Non-Matched NDC List. All of these data sources are, for example, vulnerable to some degree of inaccuracy; they also do not code or configure all product-related data in the same manner. As a result, the Non-Matched NDC List also has limitations that affect what does, or does not, appear on the list. We describe these issues below, as well as steps that may be taken to address perceived inaccuracies that relate to drug listing. We are also attaching a set of “Questions and

Answers” to help explain these issues and related matters, which you may make available to those who may review or use the Non-Matched NDC List. We believe, however, that despite imperfections, the data remain useful.

- ❖ The updated Non-Matched NDC List resulted from a comparison of NDC data included in a National Library of Medicine database as of the dates specified above, but data in those sources are periodically updated and may have changed. The fact that a product was not included in the NDC Directory as of September 30, 2009 does not preclude the possibility that it is listed with FDA now.
- ❖ The Non-Matched NDC List is not an all-inclusive list of NDCs that are not listed with FDA; there may be other marketed products with NDC numbers that are not listed with FDA, but if they are also not contained in the National Library of Medicine database they would not appear on the Non-Matched NDC List.
- ❖ The fact that an NDC is included on the Non-Matched NDC List is not a finding that the drug product is not properly listed or is illegally marketed. For example, the Non-Matched NDC List might include NDCs for products that we would not expect to find included in the NDC Directory. Reasons for this may include:
 - a firm is exempt from registration and not subject to the drug listing requirements even though it has listed a drug NDC number in other commercial databases;
 - the drug was first in commercial distribution after the firm’s last drug listing update, and the firm is not yet required to update its listing information;
 - the drug has been identified to FDA as discontinued and is no longer marketed, but it still resides on wholesaler and pharmacy shelves and thus is reflected in commercial databases;
 - the product is not identified in our listing data as a prescription drug product, e.g., it is identified as a dietary supplement, a device, or an over-the-counter drug product, but has been coded as a prescription drug product in one or more data sets used to prepare the Non-Matched NDC List. Again, we flagged for exclusion only certain products that were clearly and consistently identifiable as products that we would not expect to be included in the NDC Directory. We would need additional information about these products individually to assist in determining the reasons for such differences or what classification is most accurate.

Compounded Drug Products

An NDC identified in a PDE for a compounded drug could appear on the Non-Matched NDC List if the NDC was included in the National Library of Medicine and in the database that CMS uses for evaluating claims, but it is not listed with FDA. Under certain circumstances, a person that compounds prescription drug products is exempt from the registration and listing requirements of the Act, including:

- Pharmacies that operate under applicable local laws to regulate the dispensing of prescription drugs and only manufacture, prepare, propagate, compound, or process drugs for sale in the regular course of the practice of pharmacy, including dispensing and selling drugs at retail.
- Hospitals, clinics, and public health agencies that maintain establishments in conformance with applicable local laws regulating the practice of pharmacy or medicine, and regularly dispense drugs to patients under their care upon prescription of a licensed practitioner.
- Practitioners licensed to prescribe or administer drugs who manufacture, prepare, propagate, compound, or process drugs solely for use in their professional practice.

It is our understanding that for purposes of PDE submissions, CMS requires that compounded drugs be associated with an NDC. Thus, CMS may encounter claims/PDEs for compounded drug products that are associated with an NDC number that appears on the Non-Matched NDC List, even if it is not subject to FDA's listing requirements. We cannot determine based solely on NDC data whether a product was compounded or exempt from our rules. Pharmacies or other firms who compound drug products in the regular course of business may contact fda.cpdingteam@fda.hhs.gov with questions about whether they are subject to FDA drug registration and listing requirements.

How to Address Drug Listing Questions

Registered establishments, Part D sponsors, PBMs, pharmacies or other interested parties should contact the FDA's Drug Registration and Listing Team (nonlisted@fda.hhs.gov or 301-210-2897) if they believe that a prescription drug product NDC is incorrectly excluded from the FDA NDC Directory and, therefore, identified on the Non-Matched NDC List or if they believe the Non-Matched NDC list is otherwise inaccurate.

- Before contacting the FDA, it would be helpful and most efficient if the firm can readily provide the following information: labeler code, product code, firm name, FEI and/or DUNS, product name, and copies of the most recently submitted forms 2657 or 2658 or printed copies of the electronically submitted Structured Product Label (SPL) for Listing.

Firms that wish to list a drug product, including one that appears on the Non-Matched NDC List, may find general information about registration and listing procedures at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/DrugRegistrationandListing/default.htm>

Firms must submit drug listing information electronically. As of June 1, 2009, the FDA only accepts electronic drug establishment registration and drug listing information (unless a waiver is granted). Firms may refer to the FDA guidance for industry on *Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Listing, May 2009* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072339.pdf> for information about what listing information to submit and how to do so electronically.

As explained above, the registration and listing requirements are set forth in section 510 of the Act, 21 U.S.C. § 360, and Part 207 of FDA's regulations, 21 C.F.R. 207.

Although the next semi-annual period for listing updates required under our rules is December 2009, we want to emphasize that an establishment may update its listing(s) at any time prior to December.

We hope that this is helpful. Please contact us if you have any further questions.

Sincerely,

/s/

Deborah M. Autor, Director
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

NON-MATCHED NATIONAL DRUG CODE (NDC) LIST (CY 2010)

SUMMARY AND QUESTIONS & ANSWERS

Overview

- ❖ The Centers for Medicare and Medicaid Services (CMS) and the Office of Compliance in the FDA's Center for Drug Evaluation and Research (FDA/CDER/OC) are working on a project to
 - improve the accuracy of FDA's drug listing data; and
 - assist CMS in reducing the extent of reimbursement of claims under Medicare Part D for drugs that may not meet the statutory definition of a covered drug product, including unapproved drugs.
- On March 31, 2009, CMS published a final "Call Letter" guidance for organizations preparing to offer a Part D prescription drug benefit plan in 2010, and proposed that Part D sponsors consider the proper listing of a drug product with FDA a prerequisite for making a Part D drug coverage determination (<http://www.cms.hhs.gov/prescriptiondrugcovcontra>).
 - FDA is assisting CMS in its development of a "Non-Matched NDC List" that will support CMS's efforts to implement that guidance.
- In May 2009, CMS posted an initial version of the Non-Matched NDC List on its website. The list can be accessed from the CMS website. FDA/CDER/OC sent to CMS a letter explaining the FDA's role in providing NDC Directory data, and reviewing the Non-Matched NDC List, as well as qualifications and limitations of data reflected on the Non-Matched NDC List at least insofar as it reflects NDC Directory data maintained by FDA and to explain how firms can correct any inaccuracies. The initial list was preliminary, had no immediate impact on coverage under Medicare Part D, and may have contained inaccuracies.
- In October 2009, CMS will post an updated version of the Non-Matched NDC List on its website. As explained in the CMS Call Letter, CMS plans to use this updated version of the Non-Matched NDC List to reject PDE submissions for prescription drug products that are not posted on the FDA NDC Directory, so that those PDEs are not processed or paid automatically.

Non-Matched NDC List Questions & Answers

- **What is the Updated Non-Matched NDC List (CY 2010)?**

- A comparison of drug product NDCs included in a National Library of Medicine database as of August 3, 2009, and in the database that CMS uses to evaluate claims, against NDCs included in the FDA NDC Directory.
- The updated Non-Matched NDC List reflects NDCs that did not appear in the NDC Directory when the comparison was conducted, based on the NDC Directory as of September 30, 2009
- *Terminology Note:* CMS refers to the submission of NDCs and other information to its systems that enables CMS to make payment to plans and administer the Part D benefit as a “prescription drug event,” or “PDE,” and its means of declining certain NDC submissions as “PDE edits.”

➤ **Why was the Updated Non-Matched NDC List (CY 2010) prepared?**

- The list was prepared to help highlight NDCs for which it has not been affirmatively established that the product meets the statutory definition of covered Part D drug as specified in Section 1860D-2(e)(1)(A) of the Social Security Act.
- CMS’s Call Letter explained that it is best practice for a Part D sponsor’s drug coverage determination to begin with confirming that a prescription drug product NDC is properly listed with FDA, because FDA can only provide CMS certain regulatory status information through its regular process for drugs that are properly listed.
- Beginning in January 2010, CMS will use this updated version of the Non-Matched NDC List to reject PDE submissions for prescription drug products that are not posted on the FDA NDC Directory, so that those PDEs are not processed or paid automatically.

➤ **Are NDCs on the Updated Non-Matched NDC List (CY 2010) ineligible for coverage or reimbursement under Medicare Part D?**

- The fact that an NDC appears on the Non-Matched NDC List does not necessarily mean that it fails to satisfy the definition of a Part D drug.
- The *initial* Non-Matched NDC List posted in May 2009 helped CMS refine the process of identifying drugs that do not appear in FDA’s NDC Directory and assist Part D sponsors and others in their efforts to address drug listing or other issues before an updated version of the list was prepared.
- CMS will use this updated list to establish PDE edits for 2010, so PDEs for those NDCs are not processed automatically.

➤ **What are some of the limits of the data on the Non-Matched NDC List? Is it possible it includes NDCs that really are listed with FDA or that do not have to be listed?**

- The updated list resulted from a comparison of NDC data included in a National Library of Medicine database as of certain dates (noted above) and in the database CMS uses to evaluate claims, but data in that database is periodically updated and may have changed.

- The fact that a product is on the Non-Matched NDC List does not preclude the possibility that the product is listed with FDA now.
- The list may include NDCs for products that the FDA would not *expect* to find included in the NDC Directory. Examples include:
 - Newly introduced drugs that a firm was not yet required to identify in an update to its listing information
 - Drugs identified to the FDA as discontinued, but still reflected in drug databases
 - Products not identified in FDA listing data as a prescription drug product – such as a dietary supplement, a device, or an over-the-counter drug product - but coded as a prescription drug product in one or more of the commercial data sets used to prepare the Non-Matched NDC List

Additional information about what NDCs may and may not be included in the Non-Matched NDC list are described in FDA/CDER/OC's letter to CMS.

➤ **Do compounded drugs appear on the Non-Matched NDC List?**

- An NDC identified in a PDE for a compounded drug could appear on the Non-Matched NDC List if the NDC was included in a National Library of Medicine database and the database that CMS uses for evaluating claims, but it is not listed with FDA.
- Under certain circumstances, a person that compounds a prescription drug product is exempt from FDA's registration and drug listing requirements, including:
 - Pharmacies that operate under applicable local laws to regulate the dispensing of prescription drugs and only manufacture, prepare, propagate, compound, or process drugs for sale in the ordinary course of the practice of pharmacy.
 - Hospitals, clinics, and public health agencies that maintain establishments in conformance with applicable local laws regulating the practice of pharmacy or medicine, and regularly dispense drugs to patients under their care upon prescription of a licensed practitioner.
 - Practitioners licensed to prescribe or administer drugs who manufacture, prepare, propagate, compound, or process drugs solely for use in their professional practice.

➤ **I am a pharmacy that compounds drug products for dispensing and selling at retail to the public. Do I need to register and list with the FDA? How will I get reimbursed by CMS Medicare Part D?**

- Under 21 CFR § 207.10(a), pharmacies that do not manufacture or process drugs for sale other than in the regular course of practice of pharmacy, are exempt from registration and drug listing. Pharmacy practice includes dispensing and selling drugs at retail.
- A person that compounds drugs and has questions about whether they are subject to FDA drug registration and listing requirements may contact fda.cpdteam@fda.hhs.gov.

- FDA does not decide what products or services are eligible for coverage or what claims are reimbursed.
 - Pharmacies or other firms seeking reimbursement for extemporaneously compounded drug products should follow the process defined by CMS.
- **I think an NDC number for a product I manufacture appears on the list in error. What do I do?**
- **For questions or concerns about FDA’s NDC Directory, FDA’s drug listing procedures, or possible inaccuracies in the Non-Matched NDC List, please contact: FDA’s Drug Registration and Listing Team at (301) 210-2897 or e-mail nonlisted@fda.hhs.gov.**
 - If a firm thinks an NDC appears on the Non-Matched NDC List in error because the NDC is listed with FDA, before contacting FDA, it would be helpful and most efficient if the firm is able to readily provide the following information: labeler code, product code, firm name, FEI and/or DUNS, product name, and copies of the most recently submitted forms 2657 or 2658 or printed copies of the electronically submitted Structured Product Label (SPL) for Listing.
- **Who prepared the updated Non-Matched NDC List (CY 2010)?**
- FDA/CDER/OC staff’s compared NDCs in the FDA’s NDC Directory as of September 30, 2009 with NDC data from a National Library of Medicine database as of August 3, 2009.
 - FDA/CDER/OC staff reviewed the resulting non-matching NDC data, which contained a list of NDCs, trade names, ingredients, and other general product parameters.
 - As with the Initial Non-Matched NDC List, CDER/OC staff identified certain types of products that would not ordinarily appear on the FDA NDC Directory so they could be excluded from the Updated Non-Matched NDC List.
 - For example, FDA/CDER/OC staff identified and removed the following products from the updated Non-Matched NDC List: products that were clearly not prescription drug products in final dosage form or insulin products; products that were clearly identified as bulk chemicals, devices, or device kits; NDCs associated with products identified by FDA and establishments as discontinued; NDCs with inactive Labeler Codes; and NDCs identified by industry as incorrectly excluded from the NDC Directory (and thus identified on the Initial Non-Matched NDC List), that FDA has verified the registrant properly listed by submitting accurate and complete listing information for that product. Products that could not be clearly identified as belonging to one of the above categories may remain on the list.

- CMS compared the updated Non-Matched NDC data that the FDA provided to the database that CMS uses to evaluate claims. The resulting list is the Updated Non-Matched NDC List (CY 2010) that CMS will post on its website.
- **Who decides whether a drug is covered under Medicare Part D? What is the FDA's role in this?**
- CMS administers the Medicare Part D program.
 - FDA does not decide what products or services are eligible for coverage or what claims are reimbursed.
 - Part D sponsor coverage determinations may take into account information that FDA may be able to provide, such as whether a particular drug has, for example, been approved by FDA for safety and effectiveness. FDA can only provide Part D sponsors with this regulatory status information through its regular processes if a drug product is properly listed.
- **If an NDC is not on the Non-Matched NDC list, does that mean it is an FDA-approved drug? Is this basically a list of unapproved drugs?**
- No. Prescription drug products that are properly listed appear in the FDA's NDC Directory, but neither the assignment of an NDC number nor inclusion in the NDC Directory denotes FDA approval of the product.
 - The Non-Matched NDC List simply reflects NDCs that were not in the NDC Directory, but were listed with the database that CMS uses in connection with its evaluation of claims for eligibility for reimbursement under the Part D Prescription Drug Program; it does not indicate approval status, although some products on the list might lack FDA approval.
- **How can I tell if a prescription drug with a particular NDC number is FDA-approved?**
- While the FDA works to ensure that all marketed unapproved drug products obtain approval or are removed from the market, healthcare practitioners and consumers can use Drugs@FDA (<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>), the National Drug Code (NDC) Directory (<http://www.fda.gov/cder/ndc/database/>) or the Orange Book (<http://www.fda.gov/cder/ob/default.htm>) to determine whether a drug is FDA-approved. Drugs@FDA contains most FDA-approved drug products. The NDC Directory is limited to prescription drugs and insulin products. Search results from the NDC directory include a column marked "Application Number." FDA-approved products will have an associated NDA or ANDA number in this column. Identification of a drug product as "other" indicates that the product has not been FDA-approved (unless there is a data error or the firm did not provide the product's application number). In the Orange Book, if the product is FDA approved, then the search results will list approved products (note the application number in the "Appl No" column) by dosage form, route, and name of applicant. If the product is not in the FDA approved list, then the results will state, "No matching records found." A manufacturer can clarify whether its drug has FDA approval

by, among other things, providing the application number for the approved product when listing it with FDA.

- Questions about a firm's registration status or a product's listing status can be directed to the Drug Registration and Listing Team at nonlisted@fda.hhs.gov or (301) 210-2897.

➤ **Are NDCs on the Non-Matched List illegal?**

- The fact that an NDC is included on the Non-Matched NDC List is not a finding that the drug product is not properly listed or is illegally marketed.

➤ **Does this change the FDA requirements for drug registration and listing?**

- FDA requirements for drug registration and listing remain unchanged.
- Under section 510 of the Federal Food, Drug and Cosmetic Act, as amended (“the Act”), and Part 207 of FDA's regulations, with some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States or that are offered for import into the United States must be registered with FDA. 21 U.S.C. §§ 360(b), (c), (d), and (i).
- Every person who registers must, at the time of initial registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution. 21 U.S.C. § 360(j)(1). *See also* 21 C.F.R. 207.20.
- Drug listing information must be updated in June and December each year. These updates must include drugs not previously listed (if any), and certain changes to information for previously listed drugs.
- FDA is only accepting electronic drug establishment registration and drug listing information as of June 1, 2009 (unless a waiver is granted).
- Firms may refer to the FDA guidance for industry on *Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Listing, May 2009* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072339.pdf> for information about what listing information to submit and how to do so electronically.

➤ **Where can one get more information?**

- For questions or concerns about FDA's NDC Directory, FDA's drug listing procedures, or possible errors in the Non-Matched NDC List, please contact: FDA's Drug Registration and Listing Team at (301) 210-2897 or e-mail nonlisted@fda.hhs.gov.
- Questions about whether any drug – regardless of its FDA-approval status – is covered by CMS' Part D program must be directed to CMS, at partD_NDC@cms.hhs.gov

- For questions or concerns about electronic drug listing submissions, please contact: FDA's Drug Registration and Listing Team at (301) 210-2897 or e-mail spl@fda.hhs.gov.
- General information about the NDC Directory is available online at www.fda.gov/cder/ndc/ and FDA drug registration and listing is available online at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/DrugRegistrationandListing/default.htm>; FDA's Guidance on Electronic Registration and Listing is available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072339.pdf>
- Media inquiries can be directed to Christopher C. Kelly, FDA Press Officer, at (301) 796-4676 or Christopher.kelly@fda.hhs.gov.



HEALTH PLAN OF NEVADA
A UnitedHealthcare Company

**IMPORTANT INFORMATION REGARDING
Medicare Part D Coverage of National Drug Codes (NDCs) Not
Registered with the Food & Drug Administration (FDA)**

Effective January 1, 2010

Medicare Part D plans will **NOT** cover national drug codes (NDCs) that are not properly registered with the Food and Drug Administration (FDA). The “Non-Matched NDC List”, compiled by the Centers for Medicare and Medicaid Services (CMS) and the FDA, includes NDCs that were not present in the FDA NDC Directory.

Starting January 1, 2010, NDCs in the “Non-Matched NDC List” will reject at point-of-sale (POS) with code “70” (Product/Service Not Covered) and a message “NDC Not FDA Listed”.

For Medicare Part D eligible drugs with alternative NDCs, an additional message will instruct pharmacies to “Try alternative NDC” or “Disp NDC-9 = XXXXXXXXXX”.

IMPORTANT: Pharmacies should submit the NDC being dispensed. DO NOT submit a covered NDC simply for billing purposes.

Pharmacies should take steps to prepare for this change to ensure that unlisted products are not offered to Medicare Part D beneficiaries effective January 1, 2010. A list of NDCs on the “Non-Matched NDC List” that are most commonly submitted for Medicare Part D plans is attached. Pharmacies should review their current stock to determine if any currently held NDCs are on the “Non-Matched NDC List”.

The list is subject to change as NDCs become properly registered with the FDA.

Current FDA registration status can be verified via FDA NDC Directory at:

<http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm>

Additional information regarding the list is also available on the Senior Dimensions Web site:

www.healthplanofnevada.com.

**TO ELIMINATE PROCESSING ERRORS, PLEASE CONFIRM THE
INFORMATION ON THE MEMBER’S CARD PRIOR TO SUBMITTING PRESCRIPTIONS ON-LINE.**

Should you have any questions or require assistance, please contact the Pharmacy Services Help Desk at 702-242-7050 option #6 or 800-443-8197 option #6. Thank you for your continued support.

Please Distribute Immediately.

“Non-Matched NDC List”

NDC-9	DRUG NAME	MANUFACTURER
651620669	ACEBUTOLOL CAP 200MG	AMNEAL
651620670	ACEBUTOLOL CAP 400MG	AMNEAL
005550513	ACETAZOLAMID CAP 500MG	TEVA USA
007033018	ADRUCIL INJ 50MG/ML	SICOR
007033019	ADRUCIL INJ 50MG/ML	SICOR
005913468	ALBUTEROL NEB 1.25MG/3	WATSON
551110589	ALENDRONATE TAB 5MG	DR.REDDY'S
680840322	ALENDRONATE TAB 70MG	AMERHEALTH
625840988	ALLOPURINOL TAB 100MG	AMERHEALTH
005271704	AMANTADINE CAP 100MG	LANNETT
553900057	AMIODARONE INJ 50MG/ML	BEDFORD LB
553900105	AMIODARONE INJ 50MG/ML	BEDFORD LB
498840961	AMITRIP/CDP TAB 12.5-5MG	PAR
646790423	AMLODIPINE TAB 10MG	WOCKHARDT
651620008	AMLODIPINE TAB 10MG	AMNEAL
101350526	AMLODIPINE TAB 10MG	MARLEX
651620006	AMLODIPINE TAB 2.5MG	AMNEAL
101350524	AMLODIPINE TAB 2.5MG	MARLEX
680840238	AMLODIPINE TAB 5MG	AMERHEALTH
101350525	AMLODIPINE TAB 5MG	MARLEX
651620007	AMLODIPINE TAB 5MG	AMNEAL
680840235	AMOX/K CLAV TAB 500MG	AMERHEALTH
680840236	AMOX/K CLAV TAB 875MG	AMERHEALTH
001439939	AMOXICILLIN CAP 500MG	WEST-WARD
625840238	AMOXICILLIN CAP 500MG	AMERHEALTH
633230368	AMP-SULBACTA INJ 1-0.5GM	APPPHARMAC
633230369	AMP-SULBACTA INJ 2-1GM	APPPHARMAC
637390004	APAP/CODEINE TAB 300-30MG	MCKESSON
637390027	ATENOLOL TAB 25MG	MCKESSON
637390028	ATENOLOL TAB 50MG	MCKESSON
005171010	ATROPINE SUL INJ 1MG/ML	AMERICANRE
593900186	ATROPINE SUL OIN 1% OP	ALTAIRE
593900191	ATROPINE SUL SOL 1% OP	ALTAIRE
633230398	AZITHROMYCIN INJ 500MG	APPPHARMAC
680840278	AZITHROMYCIN TAB 250MG	AMERHEALTH
001724097	BACLOFEN TAB 20MG	IVAX PHARM
637390032	BACLOFEN TAB 20MG	MCKESSON
005913570	BALSALAZIDE CAP 750MG	WATSON
651620752	BENZAEPRIIL TAB 10MG	AMNEAL
651620753	BENZAEPRIIL TAB 20MG	AMNEAL
651620754	BENZAEPRIIL TAB 40MG	AMNEAL
651620751	BENZAEPRIIL TAB 5MG	AMNEAL
637390033	BENZTROPINE TAB 0.5MG	MCKESSON
637390034	BENZTROPINE TAB 1MG	MCKESSON
637390035	BENZTROPINE TAB 2MG	MCKESSON

NDC-9	DRUG NAME	MANUFACTURER
101350516	BETHANECHOL TAB 10MG	MARLEX
101350517	BETHANECHOL TAB 25MG	MARLEX
101350518	BETHANECHOL TAB 50MG	MARLEX
101350515	BETHANECHOL TAB 5MG	MARLEX
003787017	BICALUTAMIDE TAB 50MG	MYLAN
621750132	BICALUTAMIDE TAB 50MG	KREMERS URBAN
597621261	BISOPROL FUM TAB 10MG	GREENSTONE
633230137	BLEOMYCIN INJ 30UNIT	APPPHARMAC
637390320	BUSPIRONE TAB 10MG	MCKESSON
503830732	CALCIPOTRIEN SOL 0.005%	HI-TECH
005170132	CALCITRIOL INJ 1MCG/ML	AMERICANRE
007037311	CALCITRIOL INJ 1MCG/ML	SICOR
665910335	CALCITRIOL INJ 1MCG/ML	AAIPHARMA
597725160	CAPTOPR/HCTZ TAB 25-15MG	SANDOZ
597725161	CAPTOPR/HCTZ TAB 25-25MG	SANDOZ
597725162	CAPTOPR/HCTZ TAB 50-15MG	SANDOZ
597725163	CAPTOPR/HCTZ TAB 50-25MG	SANDOZ
605050003	CAPTOPRIL TAB 12.5MG	APOTEX
637390042	CAPTOPRIL TAB 12.5MG	MCKESSON
637390043	CAPTOPRIL TAB 25MG	MCKESSON
605050128	CARB/LEVO TAB 10-100MG	APOTEX
605050129	CARB/LEVO TAB 25-100MG	APOTEX
637390048	CARB/LEVO TAB 25-250MG	MCKESSON
605050130	CARB/LEVO TAB 25-250MG	APOTEX
625840639	CARBAMAZEPIN CHW 100MG	AMERHEALTH
672860100	CARDENE IV SOL 20/200ML	EKR THERAP
672860101	CARDENE IV SOL 20/200ML	EKR THERAP
605980120	CARDIZEM LA TAB 120MG	ABBOTT
605980121	CARDIZEM LA TAB 180MG	ABBOTT
605980122	CARDIZEM LA TAB 240MG	ABBOTT
605980123	CARDIZEM LA TAB 300MG	ABBOTT
605980124	CARDIZEM LA TAB 360MG	ABBOTT
174780710	CARTEOLOL SOL 1% OP	AKORN
001439948	CEFADROXIL TAB 1GM	WEST-WARD
605050769	CEFAZOLIN INJ 10GM	APOTEX
007813346	CEFAZOLIN INJ 10GM	SANDOZ
000744732	CEFAZOLIN INJ 1GM	HOSPIRA
007813338	CEFAZOLIN INJ 500MG	SANDOZ
668600044	CEFOTAXIME INJ 10GM	CURA PHARM
668600042	CEFOTAXIME INJ 1GM	CURA PHARM
668600043	CEFOTAXIME INJ 2GM	CURA PHARM
668600041	CEFOTAXIME INJ 500MG	CURA PHARM
597622221	CEFPROZIL TAB 500MG	GREENSTONE
007813922	CEFUROXIME INJ 1.5GM	SANDOZ
007813926	CEFUROXIME INJ 7.5GM	SANDOZ
007813918	CEFUROXIME INJ 750MG	SANDOZ
009045957	CEFUROXIME TAB 250MG	MAJOR

NDC-9	DRUG NAME	MANUFACTURER
597621083	CEFUROXIME TAB 500MG	GREENSTONE
668140602	CEFUROXIME TAB 500MG	WORLDGEN
009045958	CEFUROXIME TAB 500MG	MAJOR
001439898	CEPHALEXIN CAP 250MG	WEST-WARD
625840235	CEPHALEXIN CAP 250MG	AMERHEALTH
625840236	CEPHALEXIN CAP 500MG	AMERHEALTH
004720467	CICLOPIROX CRE 0.77%	ACTAV MID
005913471	CICLOPIROX SOL 8%	WATSON
510790402	CIPROFLOXACN TAB 250MG	UDL LABS
101350474	CIPROFLOXACN TAB 250MG	MARLEX
510790403	CIPROFLOXACN TAB 500MG	UDL LABS
003781323	CIPROFLOXACN TAB 500MG	MYLAN
101350475	CIPROFLOXACN TAB 500MG	MARLEX
101350476	CIPROFLOXACN TAB 750MG	MARLEX
458020306	CITALOPRAM TAB 10MG	PERRIGO
458020596	CITALOPRAM TAB 20MG	PERRIGO
001724742	CITALOPRAM TAB 40MG	IVAX PHARM
458020616	CITALOPRAM TAB 40MG	PERRIGO
633230282	CLINDAMYCIN INJ 150MG/ML	APPPHARMAC
633230282	CLINDAMYCIN INJ 300MG	APPPHARMAC
633230282	CLINDAMYCIN INJ 600MG	APPPHARMAC
633230282	CLINDAMYCIN INJ 900MG	APPPHARMAC
684620365	CLOBETASOL GEL 0.05%	GLENMARK
672530351	CODEINE SULF TAB 60MG	DAVA PHARM
633230393	COLISTIMETH INJ 150MG	APPPHARMAC
555150430	CORMAX SOL 0.05%	WATSON
101350506	CYCLOBENZAPR TAB 5MG	MARLEX
625840827	CYCLOSPORINE CAP 100MG	AMERHEALTH
617480115	DEMECLOCYCL TAB 150MG	VERSAPHARM
593662829	DEMECLOCYCL TAB 300MG	GLADES PHR
101350520	DICYCLOMINE CAP 10MG	MARLEX
101350521	DICYCLOMINE TAB 20MG	MARLEX
625840046	DIDANOSINE CAP 250MG	AMERHEALTH
625840048	DIDANOSINE CAP 400MG	AMERHEALTH
625840989	DIGOXIN TAB 0.125MG	AMERHEALTH
625840990	DIGOXIN TAB 0.25MG	AMERHEALTH
553900013	DIHYDROERGOT INJ 1MG/ML	BEDFORD LB
605053065	DIVALPROEX TAB 125MG DR	APOTEX
605053066	DIVALPROEX TAB 250MG DR	APOTEX
605053067	DIVALPROEX TAB 500MG DR	APOTEX
510790475	DIVALPROEX TAB 500MG DR	UDL LABS
001723687	DOXAZOSIN TAB 4MG	IVAX PHARM
618080100	DOXYCYCL HYC CAP 100MG	IMIREN
618080150	DOXYCYCL HYC CAP 50MG	IMIREN
618080210	DOXYCYCL HYC TAB 100MG	IMIREN
666850301	ENALAPRIL TAB 2.5MG	SANDOZ
005913470	EPIRUBICIN INJ 200MG	WATSON

NDC-9	DRUG NAME	MANUFACTURER
007033069	EPIRUBICIN INJ 200MG	SICOR
005913469	EPIRUBICIN INJ 50MG/25ML	WATSON
597720025	ESTRADIOL TAB 0.5MG	SANDOZ
597720026	ESTRADIOL TAB 1MG	SANDOZ
597720027	ESTRADIOL TAB 2MG	SANDOZ
605050041	ETODOLAC TAB 400MG	APOTEX
009045553	FAMOTIDINE TAB 20MG	MAJOR
009045554	FAMOTIDINE TAB 40MG	MAJOR
003785012	FELODIPINE TAB 5MG ER	MYLAN
005913214	FENTANYL DIS 100MCG/HR	WATSON
007817112	FENTANYL DIS 50MCG/HR	SANDOZ
680840287	FEXOFENADINE TAB 180MG	AMERHEALTH
680840286	FEXOFENADINE TAB 60MG	AMERHEALTH
651620642	FLECAINIDE TAB 100MG	AMNEAL
651620643	FLECAINIDE TAB 150MG	AMNEAL
651620641	FLECAINIDE TAB 50MG	AMNEAL
005550772	FLUCONAZOLE TAB 100MG	TEVA USA
005550773	FLUCONAZOLE TAB 150MG	TEVA USA
005550774	FLUCONAZOLE TAB 200MG	TEVA USA
005550771	FLUCONAZOLE TAB 50MG	TEVA USA
553900012	FLUCONAZOLE/ INJ NACL 200MG/100ML	BEDFORD LB
633230196	FLUDARABINE INJ 50MG	APPPHARMAC
633230192	FLUDARABINE INJ 50MG/2ML	APPPHARMAC
007812827	FLUOXETINE CAP 10MG	SANDOZ
007812828	FLUOXETINE CAP 20MG	SANDOZ
001724510	FLUOXETINE TAB 10MG	IVAX PHARM
007130632	FLUTICASONE OIN 0.005%	G & W LABS
001733001	FLUTICASONE SPR 50MCG	GLAXOSMITH
503830700	FLUTICASONE SPR 50MCG	HI-TECH
633040776	FOSINOPRIL TAB 20MG	RANBAXY
004094857	FOSPHENYTOIN INJ 100/2ML	HOSPIRA
007037101	FOSPHENYTOIN INJ 100/2ML	SICOR
633230403	FOSPHENYTOIN INJ 100/2ML	APPPHARMAC
646790729	FOSPHENYTOIN INJ 100/2ML	WOCKHARDT
004094857	FOSPHENYTOIN INJ 500/10ML	HOSPIRA
007037105	FOSPHENYTOIN INJ 500/10ML	SICOR
633230403	FOSPHENYTOIN INJ 500/10ML	APPPHARMAC
646790759	FUROSEMIDE INJ 10MG/ML	WOCKHARDT
100190010	FUROSEMIDE INJ 10MG/ML	BAXTER ACC
672530540	FUROSEMIDE TAB 20MG	DAVA PHARM
672530541	FUROSEMIDE TAB 40MG	DAVA PHARM
672530542	FUROSEMIDE TAB 80MG	DAVA PHARM
637390113	FUROSEMIDE TAB 80MG	MCKESSON
651620101	GABAPENTIN CAP 100MG	AMNEAL
651620102	GABAPENTIN CAP 300MG	AMNEAL
651620103	GABAPENTIN CAP 400MG	AMNEAL
005913496	GALANTAMINE CAP 8MG ER	WATSON

NDC-9	DRUG NAME	MANUFACTURER
001159911	GEMFIBROZIL TAB 600MG	GLOBAL PHA
002282900	GLIPIZIDE ER TAB 10MG	ACTAV ELIZ
002282898	GLIPIZIDE ER TAB 2.5MG	ACTAV ELIZ
633230317	GRANISETRON INJ 0.1MG/ML	APPPHARMAC
633230318	GRANISETRON INJ 1MG/ML	APPPHARMAC
633230319	GRANISETRON INJ 4MG/4ML	APPPHARMAC
672530417	GRANISETRON TAB 1MG	DAVA PHARM
101470810	GRISEOFULVIN SUS 125/5ML	PATRIOT PH
007130640	HALOBETASOL CRE 0.05%	G & W LABS
007130639	HALOBETASOL OIN 0.05%	G & W LABS
458020455	HC VALERATE CRE 0.2%	PERRIGO
007817059	HC VALERATE CRE 0.2%	SANDOZ
597728100	HC VALERATE CRE 0.2%	SANDOZ
007817063	HC VALERATE OIN 0.2%	SANDOZ
597727800	HC VALERATE OIN 0.2%	SANDOZ
003380550	HEP SOD/D5W INJ 100U/ML	BAXMEDDEL
003380550	HEP SOD/D5W INJ 50U/ML	BAXMEDDEL
004092720	HEPARIN SOD INJ 1000U/ML	HOSPIRA
004092723	HEPARIN SOD INJ 5000U/ML	HOSPIRA
009045967	HYDROCHLOROT CAP 12.5MG	MAJOR
651620119	HYDROCO/APAP TAB 10-500MG	AMNEAL
651620114	HYDROCO/APAP TAB 10-650MG	AMNEAL
651620112	HYDROCO/APAP TAB 7.5-500	AMNEAL
651620115	HYDROCO/APAP TAB 7.5-650	AMNEAL
651620118	HYDROCO/APAP TAB 7.5-750	AMNEAL
651620145	HYDROCOD/IBU TAB 7.5-200	AMNEAL
680840227	HYDROCOD/IBU TAB 7.5-200	AMERHEALTH
637390135	IBUPROFEN TAB 400MG	MCKESSON
618080230	IBUPROFEN TAB 400MG	IMIREN
651620131	IBUPROFEN TAB 400MG	AMNEAL
547380960	IBUPROFEN TAB 400MG	RICHMOND
006034022	IBUPROFEN TAB 600MG	QUALITEST
547380961	IBUPROFEN TAB 600MG	RICHMOND
006034023	IBUPROFEN TAB 800MG	QUALITEST
651620137	IBUPROFEN TAB 800MG	AMNEAL
547380962	IBUPROFEN TAB 800MG	RICHMOND
001828201	INDAPAMIDE TAB 1.25MG	IVAX PHARM
009045926	INDOMETHACIN CAP 25MG	MAJOR
009045927	INDOMETHACIN CAP 50MG	MAJOR
652710001	IPRATROPIUM SOL INHAL	ASLUNG PHA
001857322	IPRATROPIUM/ALBUTEROL SOL	SANDOZ
005913189	IRINOTECAN INJ 100/5ML	WATSON
005913189	IRINOTECAN INJ 40MG/2ML	WATSON
618080310	ISOSORB DIN TAB 10MG	IMIREN
637390149	ISOSORB DIN TAB 20MG	MCKESSON
003386330	KCL/D5W/NACL INJ .15/.45%	BAXMEDDEL
553900480	KETOROLAC INJ 15MG/ML	BEDFORD LB

NDC-9	DRUG NAME	MANUFACTURER
005170801	KETOROLAC INJ 30MG/ML	AMERICANRE
005170902	KETOROLAC INJ 60MG/2ML	AMERICANRE
602580045	LACTIC ACID LOT 10%	CYPRESS PH
605050562	LACTULOSE SOL 10GM/15	APOTEX
516724131	LAMOTRIGINE TAB 100MG	TARO
516724132	LAMOTRIGINE TAB 150MG	TARO
516724133	LAMOTRIGINE TAB 200MG	TARO
516724130	LAMOTRIGINE TAB 25MG	TARO
001857400	LEUPROLIDE INJ 1MG/0.2	SANDOZ
001214802	LEVETIRACETA SOL 500/5ML	PHARM ASSC
007815114	LEVETIRACETA TAB 1000MG	SANDOZ
007815111	LEVETIRACETA TAB 250MG	SANDOZ
684620545	LEVETIRACETA TAB 250MG	GLENMARK
007815112	LEVETIRACETA TAB 500MG	SANDOZ
684620546	LEVETIRACETA TAB 500MG	GLENMARK
007815113	LEVETIRACETA TAB 750MG	SANDOZ
162520579	LEVETIRACETA TAB 750MG	COBALT LAB
684620547	LEVETIRACETA TAB 750MG	GLENMARK
001873074	LEVO DROMORA INJ 2MG/ML	VALEANT
607580063	LEVOBUNOLOL SOL 0.25% OP	PACIFIC
607580060	LEVOBUNOLOL SOL 0.5% OP	PACIFIC
005271638	LEVOTHYROXIN TAB 137MCG	LANNETT
001857100	LISINOP/HCTZ TAB 10-12.5MG	SANDOZ
633040599	LISINOPRIL TAB 30MG	RANBAXY
605052688	LISINOPRIL TAB 40MG	APOTEX
001433190	LITHIUM CARB CAP 600MG	WEST-WARD
637390281	LOVASTATIN TAB 20MG	MCKESSON
680840133	LOVASTATIN TAB 40MG	AMERHEALTH
109740083	MAGNESIUM SU INJ 50%	PEGASUS
005913231	MELOXICAM TAB 15MG	WATSON
005913230	MELOXICAM TAB 7.5MG	WATSON
100190154	MEPERIDINE INJ 100MG/ML	BAXTER ACC
100190151	MEPERIDINE INJ 25MG/ML	BAXTER ACC
100190152	MEPERIDINE INJ 50MG/ML	BAXTER ACC
100190153	MEPERIDINE INJ 75MG/ML	BAXTER ACC
625840452	METFORMIN TAB 1000MG	AMERHEALTH
651620177	METFORMIN TAB 1000MG	AMNEAL
651620179	METFORMIN TAB 750MG ER	AMNEAL
640190554	METHADONE CON 10MG/ML	CEBERT
640190553	METHADONE CON 10MG/ML	CEBERT
553900143	METHOTREXATE INJ 1GM	BEDFORD LB
672530320	METHOTREXATE TAB 2.5MG	DAVA PHARM
553900259	METHYLPR SS INJ 1000MG	BEDFORD LB
553900210	METHYLPR SS INJ 125MG	BEDFORD LB
553900258	METHYLPR SS INJ 500MG	BEDFORD LB
005912229	METOCLOPRAM TAB 10MG	WATSON
633040846	METOCLOPRAM TAB 10MG	RANBAXY

NDC-9	DRUG NAME	MANUFACTURER
005912228	METOCLOPRAM TAB 5MG	WATSON
581770368	METOPROLOL TAB 100MG ER	ETHEX
593662876	METRONIDAZOL CRE 0.75%	GLADES PHR
007130633	METRONIDAZOL CRE 0.75%	G & W LABS
674050110	METRONIDAZOL CRE 0.75%	HARRIS PHARM
593662866	METRONIDAZOL LOT 0.75%	GLADES PHR
001850020	MIRTAZAPINE TAB 15MG	SANDOZ
633230191	MITOMYCIN INJ 5MG	APPPHARMAC
105180105	MITOXANTRON INJ 20MG	APPPHARMAC
105180105	MITOXANTRON INJ 25MG	APPPHARMAC
633230132	MITOXANTRON INJ 2MG/ML	APPPHARMAC
105180105	MITOXANTRON INJ 30MG	APPPHARMAC
162520613	MOEXIPR/HCTZ TAB 15-12.5	COBALT LAB
621750720	MOEXIPR/HCTZ TAB 15-12.5	KREMERS URBAN
162520614	MOEXIPR/HCTZ TAB 15-25MG	COBALT LAB
621750725	MOEXIPR/HCTZ TAB 15-25MG	KREMERS URBAN
162520612	MOEXIPR/HCTZ TAB 7.5-12.5	COBALT LAB
621750712	MOEXIPR/HCTZ TAB 7.5-12.5	KREMERS URBAN
162520611	MOEXIPRIL TAB 15MG	COBALT LAB
605050272	MOEXIPRIL TAB 15MG	APOTEX
162520610	MOEXIPRIL TAB 7.5MG	COBALT LAB
605050271	MOEXIPRIL TAB 7.5MG	APOTEX
007130634	MOMETASONE CRE 0.1%	G & W LABS
674050100	MOMETASONE CRE 0.1%	HARRIS PHARM
007130635	MOMETASONE OIN 0.1%	G & W LABS
674050300	MOMETASONE OIN 0.1%	HARRIS PHARM
007130701	MOMETASONE SOL 0.1%	G & W LABS
007817067	MOMETASONE SOL 0.1%	SANDOZ
674050275	MOMETASONE SOL 0.1%	HARRIS PHARM
684620203	MORPHINE SUL TAB 30MG	GLENMARK
510790721	MYCOPHENOLAT CAP 250MG	UDL LABS
510790379	MYCOPHENOLAT TAB 500MG	UDL LABS
005551119	NALBUPHINE INJ 10MG/ML	TEVA USA
005551120	NALBUPHINE INJ 20MG/ML	TEVA USA
100190039	NALOXONE INJ 0.4MG/ML	BAXTER ACC
551110366	NAPROXEN TAB 250MG	DR.REDDY'S
458020121	NAPROXEN TAB 250MG	PERRIGO
651620188	NAPROXEN TAB 250MG	AMNEAL
547380570	NAPROXEN TAB 250MG	RICHMOND
551110367	NAPROXEN TAB 375MG	DR.REDDY'S
651620189	NAPROXEN TAB 375MG	AMNEAL
547380571	NAPROXEN TAB 375MG	RICHMOND
551110368	NAPROXEN TAB 500MG	DR.REDDY'S
458020631	NAPROXEN TAB 500MG	PERRIGO
651620193	NAPROXEN SOD TAB 275MG	AMNEAL
651620194	NAPROXEN SOD TAB 550MG	AMNEAL
621750260	NIFEDIPINE TAB 30MG ER	KREMERS URBAN

NDC-9	DRUG NAME	MANUFACTURER
680840142	NIFEDIPINE TAB 30MG ER	AMERHEALTH
621750261	NIFEDIPINE TAB 60MG ER	KREMERS URBAN
680840143	NIFEDIPINE TAB 60MG ER	AMERHEALTH
621750262	NIFEDIPINE TAB 90MG ER	KREMERS URBAN
231550108	NIMODIPINE CAP 30MG	HERITAGE
000891303	NITROGLYCER DIS 0.4MG/HR	GRACEWAY
551110311	NIZATIDINE CAP 300MG	DR.REDDY'S
398223015	NYSTATIN POW 100000	X-GEN
621750136	OMEPRAZOLE CAP 40MG	KREMERS URBAN
007814014	OMNITROPE INJ 5.8MG	SANDOZ
001439890	ONDANSETRON INJ 2MG/ML	WEST-WARD
633230374	ONDANSETRON INJ 40/20ML	APPPHARMAC
633230373	ONDANSETRON INJ 4MG/2ML	APPPHARMAC
501110945	ONDANSETRON TAB 4MG ODT	TEVA USA
597622993	ONDANSETRON TAB 8MG	GREENSTONE
501110946	ONDANSETRON TAB 8MG ODT	TEVA USA
681880480	ORAPRED ODT TAB 10MG	SCIELE PHA
553900059	ORPHENADRINE INJ 30MG/ML	BEDFORD LB
637390195	OXYBUTYNIN TAB 5MG	MCKESSON
651620206	OXYCOD/APAP TAB 10-650MG	AMNEAL
651620203	OXYCOD/APAP TAB 5-325MG	AMNEAL
553900204	PAMIDRONATE INJ 30/10ML	BEDFORD LB
633230735	PAMIDRONATE INJ 90/10ML	OTN
633230735	PAMIDRONATE INJ 90/10ML	APPPHARMAC
004062097	PAROXETINE TAB 10MG	MALLINCKRO
004062099	PAROXETINE TAB 30MG	MALLINCKRO
597621537	PENICILLN VK TAB 500MG	GREENSTONE
651620212	PHENYTOIN EX CAP 100MG	AMNEAL
512850769	PLAN B TAB 0.75MG	TEVA USA
005913204	PODOFILOX SOL 0.5%	WATSON
633230321	POLYMYXIN B INJ 500000	APPPHARMAC
637390306	POT CL MICRO TAB 20MEQ CR	MCKESSON
101350498	PRAVASTATIN TAB 10MG	MARLEX
101350499	PRAVASTATIN TAB 20MG	MARLEX
101350500	PRAVASTATIN TAB 40MG	MARLEX
003788280	PRAVASTATIN TAB 80MG	MYLAN
107687283	PREDNISONE TAB 10MG	PERRIGO
107687085	PREDNISONE TAB 20MG	PERRIGO
107687733	PREDNISONE TAB 5MG	PERRIGO
101350522	PRIMIDONE TAB 250MG	MARLEX
669930810	PROCHLORPER TAB 10MG	PRASCO LAB
669930805	PROCHLORPER TAB 5MG	PRASCO LAB
668600098	PROMETHAZINE INJ 25MG/ML	CURA PHARM
668600099	PROMETHAZINE INJ 50MG/ML	CURA PHARM
101350514	PROMETHAZINE TAB 12.5MG	MARLEX
101350495	PROMETHAZINE TAB 25MG	MARLEX
101350496	PROMETHAZINE TAB 50MG	MARLEX

NDC-9	DRUG NAME	MANUFACTURER
680840211	PROPRANOLOL CAP 120MG ER	AMERHEALTH
680840212	PROPRANOLOL CAP 160MG ER	AMERHEALTH
680840209	PROPRANOLOL CAP 60MG ER	AMERHEALTH
680840210	PROPRANOLOL CAP 80MG ER	AMERHEALTH
633040549	QUINAPRIL TAB 10MG	RANBAXY
633040550	QUINAPRIL TAB 20MG	RANBAXY
633040551	QUINAPRIL TAB 40MG	RANBAXY
633040548	QUINAPRIL TAB 5MG	RANBAXY
002282695	RAMIPRIL CAP 2.5MG	ACTAV ELIZ
001214727	RANITIDINE SYP 150/10ML	PHARM ASSC
421920505	RANITIDINE SYP 15MG/ML	BROOKSTONE
651620253	RANITIDINE TAB 150MG	AMNEAL
651620254	RANITIDINE TAB 300MG	AMNEAL
000851351	REBETOL CAP 200MG	SCHERING
000851385	REBETOL CAP 200MG	SCHERING
646790553	RISPERIDONE TAB 0.25MG	WOCKHARDT
162520559	RISPERIDONE TAB 0.5MG	COBALT LAB
009045974	RISPERIDONE TAB 0.5MG	MAJOR
162520560	RISPERIDONE TAB 1MG	COBALT LAB
009045975	RISPERIDONE TAB 1MG	MAJOR
162520561	RISPERIDONE TAB 2MG	COBALT LAB
009045976	RISPERIDONE TAB 2MG	MAJOR
009045977	RISPERIDONE TAB 3MG	MAJOR
162520563	RISPERIDONE TAB 4MG	COBALT LAB
009045978	RISPERIDONE TAB 4MG	MAJOR
672530700	SELEGILINE CAP 5MG	DAVA PHARM
101350509	SIMVASTATIN TAB 10MG	MARLEX
680840163	SIMVASTATIN TAB 20MG	AMERHEALTH
101350510	SIMVASTATIN TAB 20MG	MARLEX
101350511	SIMVASTATIN TAB 40MG	MARLEX
007815070	SIMVASTATIN TAB 5MG	SANDOZ
101350508	SIMVASTATIN TAB 5MG	MARLEX
004062069	SIMVASTATIN TAB 80MG	MALLINCKRO
101350512	SIMVASTATIN TAB 80MG	MARLEX
005271443	SMZ/TMP DS TAB 800-160	LANNETT
651620272	SMZ/TMP DS TAB 800-160	AMNEAL
001214793	SMZ-TMP SUS	PHARM ASSC
005271442	SMZ-TMP TAB 400-80MG	LANNETT
651620271	SMZ-TMP TAB 400-80MG	AMNEAL
009045807	SMZ-TMP TAB 400-80MG	MAJOR
003386333	SOD CHLORIDE INJ 0.45%	BAXMEDDEL
003388018	SOD CHLORIDE INJ 0.9%	BAXMEDDEL
638070102	SOD CHLORIDE INJ 0.9%	EXCELSIOR
633230088	SOD CHLORIDE INJ 23.4%	APPPHARMAC
633040097	SUMATRIPTAN TAB 25MG	RANBAXY
633040098	SUMATRIPTAN TAB 50MG	RANBAXY
637390269	TAMOXIFEN TAB 10MG	MCKESSON

NDC-9	DRUG NAME	MANUFACTURER
646790209	TERBINAFINE TAB 250MG	WOCKHARDT
005550544	TERBINAFINE TAB 250MG	TEVA USA
005740820	TESTOST CYP INJ 200MG/ML	PADDOCK
165710140	TIMOLOL MAL SOL 0.25% OP	PACK PHARM
685520740	TIZANIDINE TAB 2MG	DECA PHARM
618083200	TMP/SMZ DS TAB 160-800	IMIREN
672530754	TOPIRAMATE TAB 200MG	DAVA PHARM
000540076	TORSEMIDE TAB 10MG	ROXANE
000540077	TORSEMIDE TAB 20MG	ROXANE
547380210	TRAMADOL HCL TAB 50MG	RICHMOND
101350519	TRAMADOL HCL TAB 50MG	MARLEX
658620165	TRANDOLAPRIL TAB 2MG	AUROBINDO
605052659	TRAZODONE TAB 300MG	APOTEX
637390245	TRAZODONE TAB 50MG	MCKESSON
458020182	TRETINOIN CRE 0.025%	PERRIGO
458020361	TRETINOIN CRE 0.05%	PERRIGO
458020183	TRETINOIN CRE 0.1%	PERRIGO
458020362	TRETINOIN GEL 0.01%	PERRIGO
458020363	TRETINOIN GEL 0.025%	PERRIGO
680840213	URSODIOL CAP 300MG	AMERHEALTH
005914012	VALPROIC ACD CAP 250MG	WATSON
637390251	VALPROIC ACD CAP 250MG	MCKESSON
233600153	VANCOMYCIN INJ 5GM	AKORNSTRID
553900069	VINORELBINE INJ 10MG/ML	BEDFORD LB
100190970	VINORELBINE INJ 10MG/ML	BAXTER ACC
553900070	VINORELBINE INJ 50MG/5ML	BEDFORD LB
634590300	VIVITROL INJ 380MG	CEPHALON
647200323	ZALEPLON CAP 10MG	COREPHARMA
001433910	ZALEPLON CAP 10MG	WEST-WARD
647200322	ZALEPLON CAP 5MG	COREPHARMA
001433909	ZALEPLON CAP 5MG	WEST-WARD
000540052	ZIDOVUDINE TAB 300MG	ROXANE
000540087	ZOLPIDEM TAB 10MG	ROXANE
669930715	ZOLPIDEM TAB 5MG	PRASCO LAB
000540086	ZOLPIDEM TAB 5MG	ROXANE
680840225	ZOLPIDEM TAB 5MG	AMERHEALTH
680840190	ZONISAMIDE CAP 25MG	AMERHEALTH
551110403	ZONISAMIDE CAP 50MG	DR.REDDY'S